Page 293 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Compound heterozygous DPYD variant allele carriers
34. Francioli L, Menelaou A, Pulit S, et al. Genome of the Netherlands Consortium. Whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat Genet. 2014;46(8):818-825.
35. Python. Python Software Foundation©. 2001; https://www.python.org/.
36. IGSR. The International Genome Sample Resource. 2008; http://www.internationalgenome.org/
Accessed 29th June 2017.
37. Li H. Tabix: fast retrieval of sequence features from generic TAB-delimited files. Bioinformatics.
2011;27(5):718-719.
38. R. Core Team. R: A Language and Environment for Statistical Computing. 2018; https://www.R-
project.org.
39. Toffoli G, Giodini L, Buonadonna A, et al. Clinical validity of a DPYD-based pharmacogenetic test
to predict severe toxicity to fluoropyrimidines. Int J Cancer. 2015;137(12):2971-2980.
40. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting
from a novel compound heterozygote genotype. Clin Cancer Res. 2002;8(3):768-774.
41. Jacobs BAW, Deenen MJ, Pluim D, et al. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human
volunteers. Br J Clin Pharmacol. 2016;82(3):706-716.
42. Meulendijks D, Henricks LM, Amstutz U, et al. Rs895819 in MIR27A improves the predictive value
of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. Int J Cancer. 2016;138(11):2752-2761.
11
291